个人中心 - 老虎社区

彻夜笙歌

IP属地：未知

帖子 · 4帖子 · 4
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- 彻夜笙歌彻夜笙歌
  ·05-13
  $MIRXES-B(02629)$ Mirxes觅瑞停牌快一个半月，市场各种猜测。看了5月10日这两份文件心才终于落了地。补充公告显示：预付款问题主要是供应商评估流程有漏洞，不是资金黑洞；大额现金流出里，审计师标注属于常规期后事项，并非定性有问题。公司主动请普华永道整改内控，IIC调查也快收尾。希望觅瑞能尽快复牌吧！
  580 评论
  2
  分享
  举报
- 彻夜笙歌彻夜笙歌
  ·02-27
  $MIRXES-B(02629)$ 2月23日，Mirxes觅瑞发布自愿性公告，宣布其结直肠癌早筛前瞻性临床研究CADENCE CRC已完成全部入组。该研究是东盟地区首项、也是规模最大的血液肠癌筛查注册性研究，标志着觅瑞肠癌早筛临床验证进入关键阶段，为后续商业化落地奠定坚实基础，充分体现出公司深耕东盟与中国市场的战略布局取得显著成效。
  575 评论
  1
  分享
  举报
- 彻夜笙歌彻夜笙歌
  ·2025-11-20
  $MIRXES-B(02629)$ 觅瑞觅小卫®已经获得中国国家药品监督管理局（NMPA）第三类医疗器械注册证了，这意味着产品可以直接作为胃癌早期筛查的独立工具投入临床应用。期待！
  1,020 评论
  1
  分享
  举报
- 彻夜笙歌彻夜笙歌
  ·2025-06-24
  现在港股市场怎么样？
  651 评论
  2
  分享
  举报
暂无关注

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4213855129601350","uuid":"4213855129601350","gmtCreate":1750751942174,"gmtModify":1750751952626,"name":"彻夜笙歌","pinyin":"cysgcheyeshengge","introduction":"","introductionEn":null,"signature":"","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":0,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[],"userBadgeCount":0,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":563691375507616,"gmtCreate":1778654357952,"gmtModify":1778654621857,"author":{"id":"4213855129601350","authorId":"4213855129601350","name":"彻夜笙歌","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4213855129601350","idStr":"4213855129601350"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02629\">$MIRXES-B(02629)$</a> Mirxes觅瑞停牌快一个半月，市场各种猜测。看了5月10日这两份文件心才终于落了地。补充公告显示：预付款问题主要是供应商评估流程有漏洞，不是资金黑洞；大额现金流出里，审计师标注属于常规期后事项，并非定性有问题。公司主动请普华永道整改内控，IIC调查也快收尾。希望觅瑞能尽快复牌吧！","listText":"<a href=\"https://laohu8.com/S/02629\">$MIRXES-B(02629)$</a> Mirxes觅瑞停牌快一个半月，市场各种猜测。看了5月10日这两份文件心才终于落了地。补充公告显示：预付款问题主要是供应商评估流程有漏洞，不是资金黑洞；大额现金流出里，审计师标注属于常规期后事项，并非定性有问题。公司主动请普华永道整改内控，IIC调查也快收尾。希望觅瑞能尽快复牌吧！","text":"$MIRXES-B(02629)$ Mirxes觅瑞停牌快一个半月，市场各种猜测。看了5月10日这两份文件心才终于落了地。补充公告显示：预付款问题主要是供应商评估流程有漏洞，不是资金黑洞；大额现金流出里，审计师标注属于常规期后事项，并非定性有问题。公司主动请普华永道整改内控，IIC调查也快收尾。希望觅瑞能尽快复牌吧！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/563691375507616","isVote":1,"tweetType":1,"viewCount":580,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":537152470570080,"gmtCreate":1772161627904,"gmtModify":1772161748168,"author":{"id":"4213855129601350","authorId":"4213855129601350","name":"彻夜笙歌","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4213855129601350","idStr":"4213855129601350"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02629\">$MIRXES-B(02629)$</a> 2月23日，Mirxes觅瑞发布自愿性公告，宣布其结直肠癌早筛前瞻性临床研究CADENCE CRC已完成全部入组。该研究是东盟地区首项、也是规模最大的血液肠癌筛查注册性研究，标志着觅瑞肠癌早筛临床验证进入关键阶段，为后续商业化落地奠定坚实基础，充分体现出公司深耕东盟与中国市场的战略布局取得显著成效。","listText":"<a href=\"https://laohu8.com/S/02629\">$MIRXES-B(02629)$</a> 2月23日，Mirxes觅瑞发布自愿性公告，宣布其结直肠癌早筛前瞻性临床研究CADENCE CRC已完成全部入组。该研究是东盟地区首项、也是规模最大的血液肠癌筛查注册性研究，标志着觅瑞肠癌早筛临床验证进入关键阶段，为后续商业化落地奠定坚实基础，充分体现出公司深耕东盟与中国市场的战略布局取得显著成效。","text":"$MIRXES-B(02629)$ 2月23日，Mirxes觅瑞发布自愿性公告，宣布其结直肠癌早筛前瞻性临床研究CADENCE CRC已完成全部入组。该研究是东盟地区首项、也是规模最大的血液肠癌筛查注册性研究，标志着觅瑞肠癌早筛临床验证进入关键阶段，为后续商业化落地奠定坚实基础，充分体现出公司深耕东盟与中国市场的战略布局取得显著成效。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/537152470570080","isVote":1,"tweetType":1,"viewCount":575,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":502171097158448,"gmtCreate":1763619336208,"gmtModify":1763621032799,"author":{"id":"4213855129601350","authorId":"4213855129601350","name":"彻夜笙歌","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4213855129601350","idStr":"4213855129601350"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/02629\">$MIRXES-B(02629)$</a> 觅瑞觅小卫®已经获得中国国家药品监督管理局（NMPA）第三类医疗器械注册证了，这意味着产品可以直接作为胃癌早期筛查的独立工具投入临床应用。期待！","listText":"<a href=\"https://laohu8.com/S/02629\">$MIRXES-B(02629)$</a> 觅瑞觅小卫®已经获得中国国家药品监督管理局（NMPA）第三类医疗器械注册证了，这意味着产品可以直接作为胃癌早期筛查的独立工具投入临床应用。期待！","text":"$MIRXES-B(02629)$ 觅瑞觅小卫®已经获得中国国家药品监督管理局（NMPA）第三类医疗器械注册证了，这意味着产品可以直接作为胃癌早期筛查的独立工具投入临床应用。期待！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/502171097158448","isVote":1,"tweetType":1,"viewCount":1020,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":449438571815504,"gmtCreate":1750752708558,"gmtModify":1750753415777,"author":{"id":"4213855129601350","authorId":"4213855129601350","name":"彻夜笙歌","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4213855129601350","idStr":"4213855129601350"},"themes":[],"title":"","htmlText":"现在港股市场怎么样？","listText":"现在港股市场怎么样？","text":"现在港股市场怎么样？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/449438571815504","isVote":1,"tweetType":1,"viewCount":651,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"following","isTTM":false}